STAAR Surgical's stock fell sharply after the ophthalmic device maker announced the appointment of interim co-CEOs, fueling investor uncertainty following the CEO's recent departure and a failed takeover attempt.
The FDA has cleared Intuitive Surgical's latest robotic system for use in certain heart surgeries, marking a strategic expansion into one of healthcare's largest and most complex service lines and potentially reshaping hospital capital planning for robotics.
CONMED's latest earnings reveal a strategic pivot towards higher-growth surgical platforms, moving away from slower gastroenterology lines. While sales climbed, profitability softened, setting the stage for a crucial transition year as the market weighs the company's reset valuation against its ambitious 2026 roadmap.
While fully autonomous robotic surgeons remain on the horizon, the foundational technology and data ecosystems being built today are setting the stage for a transformative shift. Two industry giants, Intuitive Surgical and Medtronic, offer investors distinct pathways to capitalize on this evolving landscape.
The FDA has cleared Intuitive Surgical's da Vinci 5 robotic system for select complex cardiac procedures, a move that could reshape the landscape of minimally invasive heart surgery and open a significant new market for the industry leader.
Amid a steep 60% annual share price decline, investment firm Chicago Capital has significantly reduced its position in PROCEPT BioRobotics, a developer of robotic systems for urological surgery, signaling a portfolio risk reassessment.
Stryker Corporation's latest earnings report, driven by its MedSurg, Neurotechnology divisions and the Mako surgical robot, has reignited investor debate. With shares near $370 and a bullish fair value estimate of $427, analysts are weighing robust growth against a premium valuation.
The medical technology giant reported double-digit organic sales growth and robust profitability for 2025, driven by record installations of its Mako surgical robots. While projecting continued strength for 2026, management acknowledged incremental tariff pressures but expressed confidence in the company's ability to sustain margin expansion.
Merck & Co. is laying the groundwork for its future in oncology beyond Keytruda, announcing a strategic investment in biotech Eikon Therapeutics and a major collaboration with diagnostic leader Guardant Health. The moves signal a targeted, partnership-driven strategy to bolster its pipeline and diagnostics capabilities in the competitive cancer therapy market.
Saks Global is closing most of its Saks OFF 5TH off-price stores across the U.S., leaving only a dozen locations open as it refocuses on core luxury and full-price retail after a recent Chapter 11 filing.
Craig-Hallum and Northland Securities have both lowered price targets for MiMedx Group (MDXG), citing near-term uncertainty following new CMS billing guidance for skin substitute products, though both firms maintain positive long-term ratings.
Verizon Communications (VZ) surged nearly 12% after a robust Q4 2023 report, record postpaid growth, and a major share repurchase program. The telecom giant's confident 2026 outlook and strategic acquisition of Frontier assets signal a potential pivot, though questions about debt and valuation persist.
Tenet Healthcare has regained complete ownership of its revenue cycle management subsidiary Conifer, buying out CommonSpirit Health's minority stake in a deal valued at nearly $2.7 billion. The move signals Tenet's renewed commitment to the business and plans for significant AI investment.
Senator James Lankford's annual oversight report details what he calls wasteful federal spending, including controversial NIH-funded projects on transgender-related animal testing and aborted fetal tissue research, reigniting debates on scientific priorities and fiscal responsibility.
Goldman Sachs CEO David Solomon, while optimistic on global markets, forecasts a deliberate deceleration in talent acquisition for 2026 as the bank sharpens its focus on operational efficiency and strategic resource allocation.
Chinese biotech firm Arctic Vision moves to create an integrated ophthalmology powerhouse by acquiring MDCO Technology's device business, combining drug and device expertise to address unmet needs in eye care.
The S&P 500 is home to market leaders, but not all its constituents are created equal. We examine one company navigating challenges and two others positioned for potential growth, providing context on their valuations and market positions.
While robust cash generation signals financial health, it doesn't guarantee stock outperformance. We analyze three cash-rich firms, highlighting one standout and two where strong cash flow masks underlying risks.
One of Ethereum's largest holders faces a potential multi-billion dollar liquidation as prices slide, prompting urgent deleveraging moves that could ripple across crypto markets.
Amidst a complex global economic backdrop, Asia's equity markets are hiding gems trading significantly below their estimated intrinsic value. We spotlight three companies—from gaming to aviation and medtech—that our cash flow analysis suggests are deeply discounted, offering potential for investors with an eye on long-term fundamentals.
